Form 8-K - Current report:
SEC Accession No. 0001664710-25-000038
Filing Date
2025-04-18
Accepted
2025-04-18 17:00:13
Documents
14
Period of Report
2025-04-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20250417.htm   iXBRL 8-K 38012
2 EX-10.1 exhibit10141725.htm EX-10.1 40952
  Complete submission text file 0001664710-25-000038.txt   215275

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20250417.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20250417_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20250417_pre.xml EX-101.PRE 13046
16 EXTRACTED XBRL INSTANCE DOCUMENT kros-20250417_htm.xml XML 2823
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 25850817
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)